

QTc prolongations as a result of drug interactions of CD4/6 inhibitors

Aleksandra Grela-Wojewoda¹, Mirosława Puskulluoglu¹, Joanna Lompart¹, Marek Ziobro¹, Ewa Konduracka²

¹Department of Clinical Oncology, Maria Skłodowska-Curie National Research Institute of Oncology, Krakow Branch, Krakow, Poland

²Department of Coronary Disease and Heart Failure, Jagiellonian University Medical College, John Paul II Hospital, Krakow, Poland





Figure 1. EKG (15.07.21): sinus bradycardia 54/min. Intermed. heart axis. The interval P-R: 130 ms, QTc – 520 ms, flat T in V2, shallow negative T in V3, flat T in V4

A 45-year-old woman was diagnosed with metastatic breast cancer with dissemination to the bones and mediastinal lymph nodes of the breast. Taking into account the biological type (luminal B, *HER2*-negative) and the low dynamics of the disease, the best therapeutic option was to use hormone therapy in combination selective oestrogen receptor downregulator – fulvestrant with the cyclin-dependent kinase 4/6 (CDK 4/6) inhibitor. The therapy was initiated in July 2021. The pre-treatment electrocardiogram (ECG) was normal. On day 15 the control ECG showed heart rate 54/min and QTc – 520 ms. During therapy, mycoses of the esophagus were diagnosed and fluconazole 50 mg tabletes QD were ordered. Due to persisting dysphagia, antifungal agents were continued for the next 10 days, together only with hormonal therapy. A control ECG 3 weeks later was normal and the CDK 4/6 therapy was

restarted. Conclusion: protein kinase inhibitors used in molecularly-targeted oncology drugs are cardiotoxic and can cause various disorders of the cardiovascular system. This group of agents includes CDK 4/6 inhibitors that occasionally prolong the QTc interval [1]. Cyclin-dependent kinase 4/6 inhibitors are metabolized by CYP3A enzymes and inhibit CYP3A themselves. Co-administration with a strong CYP3A inhibitor increases cardiotoxicity of CDK 4/6 inhibitors and should be avoided [2].

References

1. Grela-Wojewoda A, Pacholczak-Madej R, Adamczyk A, et al. Cardiotoxicity Induced by Protein Kinase Inhibitors in Patients with Cancer. *Int J Mol Sci.* 2022; 23(5): 2815, doi: 10.3390/ijms23052815, indexed in Pubmed: 35269958.
2. Rascon K, Flajc G, De Angelis C, et al. Ribociclib in HR+/HER2- Advanced or Metastatic Breast Cancer Patients. *Ann Pharmacother.* 2019; 53(5): 501–509, doi: 10.1177/1060028018817904, indexed in Pubmed: 30522347.

How to cite:

Grela-Wojewoda A, Puskulluoglu M, Lompart J, Ziobro M, Konduracka E. *QTc prolongations as a result of drug interactions of CD4/6 inhibitors.* *NOWOTWORY J Oncol* 2022; 72: 258–258.

This article is available in open access under Creative Common Attribution-Non-Commercial-No Derivatives 4.0 International (CC BY-NC-ND 4.0) license, allowing to download articles and share them with others as long as they credit the authors and the publisher, but without permission to change them in any way or use them commercially.